MSN LABORATORIES PRIVATE LIMITED

MSN House, Plot No. C-24, Sanath Nagar Industrial Estate, Hyderabad, Telangana, 印度

别名:

msn laboratories ltd.,

msn laboratories private limited 317, 320, 321, 322, 323, 604 & 605, rudraram, patancheru (mandal), sangareddy district, telangana 502329, india

msn laboratories private limited, nandigama

概览

试验阶段分布

阶段

试验数

占比

3 期

48.1%

不适用

14.8%

1 期

7.4%

Unknown

3.7%

试验状态分布

已完成

29.6%

尚未招募

29.6%

招募中

25.9%

Unknown

14.8%

相关临床试验

该机构主办的试验（27）

This is the study to check the safety and efficacy of Vibegron 75 mg tablet in comparison with Mirabegron ER 25mg/50mg Tablet in Patients with Overactive Bladder

An Open Label Balanced Randomized Single Dose Two Treatment Two Sequence Two Period Two Way Crossover Oral Bioequivalence Study Comparing Vonoprazan Tablets 20 mg

尚未招募

interventional

Nov 202432 名受试者

An Open Label Balanced Randomized Single Dose Two Treatment Two Sequence Two Period Two Way Crossover Oral Bioequivalence Study Comparing Vonoprazan Tablets 20 mg

尚未招募

interventional

Nov 202432 名受试者

Pharmacokinetic Study of Pazopanib in Advanced Renal Cell Carcinoma patients

招募中

interventional

Sep 202352 名受试者

Pharmacokinetic Study of Pazopanib in Advanced Renal Cell Carcinoma patients

招募中

interventional

May 202252 名受试者

A Clinical Trial to Evaluate the Efficacy and Safety of Plecanatide in Subjects with Chronic Idiopathic Constipation or Irritable Bowel Syndrome with Constipation.

A Clinical Trial to Evaluate the Efficacy, Safety of Fesoterodine Fumarate Extended Release Tablets 4 mg / 8 mg Versus Solifenacin Succinate Tablets 5 mg/10 mg in Adult Patients Diagnosed with Overactive Bladder with Symptoms of Urge Urinary Incontinence, Urgency, and Frequency.

A Bioequivalence Study of Dabigatran Etexilate Capsules under Fasting Conditions

第 1 页，共 4 页

药物批准

按机构分类的批准

NMPA

National Medical Products Administration

药物批准

FDA

Food and Drug Administration

药物批准

PHILIPPINES

Philippines FDA

药物批准

SFDA

Saudi Food and Drug Authority

药物批准

NPRA

National Pharmaceutical Regulatory Agency

药物批准

近期批准

XOMICIB 60 (Carfilzomib lyophilized powder for solution for infusion 60 mg/vial)

NPRA

2026-08-14

FEBUDAY 40 (Febuxostat Film-Coated Tablets 40mg)

NPRA

2026-08-07

FEBUDAY 80 (FEBUXOSTAT FILM-COATED TABLETS 80MG )

NPRA

2026-08-07

SUPAGREL 60 (Ticagrelor Film-Coated Tablets 60 mg)

NPRA

2026-05-29

SUPAGREL 90 (Ticagrelor Film-Coated Tablets 90 mg)

NPRA

2026-05-29

DABIFIB 110 (Dabigatran Etexilate Hard Capsules 110 mg)

NPRA

2026-04-24

DABIFIB 150 (Dabigatran Etexilate Hard Capsules 150 mg)

NPRA

2026-04-24

DABIFIB 75 (Dabigatran Etexilate Hard Capsules 75 mg)

NPRA

2026-04-24

OSELOW 30 (Oseltamivir Hard Capsules 30 mg)

NPRA

2026-02-13

OSELOW 75 (Oseltamivir Hard Capsules 75 mg)

NPRA

2026-02-13

资讯

暂无资讯文章

返回机构列表